메뉴 건너뛰기
Inflammatory Bowel Diseases
Volumn 18, Issue 4, 2012, Pages 795-796
Setting a high threshold for noninferiority: Mesalamine and budesonide in Crohn's disease
Author keywords

[No Author keywords available]
Indexed keywords

BUDENOFALK; BUDESONIDE; EUDRAGIT; MESALAZINE;
EID: 84858702103     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21813     Document Type: Note
Times cited : (3)
References (8)
  • 1
    • 79953788479 scopus 로고    scopus 로고
    • Efficacy of 5-aminosalicylates in Crohn's disease: Systematic review and meta-analysis
    • Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106:617-629.
    • (2011) Am J Gastroenterol , vol.106 , pp. 617-629
    • Ford, A.C.1    Kane, S.V.2    Khan, K.J.3
  • 2
    • 79952196928 scopus 로고    scopus 로고
    • Aminosalicylates for induction of remission or response in Crohn's disease
    • CD008870
    • Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2010;8:CD008870.
    • (2010) Cochrane Database Syst Rev , vol.8
    • Lim, W.C.1    Hanauer, S.2
  • 3
    • 14644417773 scopus 로고    scopus 로고
    • Budesonide as maintenance treatment in Crohn's disease: A placebo-controlled trial
    • DOI 10.1111/j.1365-2036.2005.02338.x
    • Hanauer S, Sandborn WJ, Persson A, et al. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment Pharmacol Ther. 2005;21:363-371. (Pubitemid 40320545)
    • (2005) Alimentary Pharmacology and Therapeutics , vol.21 , Issue.4 , pp. 363-371
    • Hanauer, S.1    Sandborn, W.J.2    Persson, A.3    Persson, T.4
  • 4
    • 0028071632 scopus 로고
    • Oral budesonide for active Crohn's disease
    • Canadian Inflammatory Bowel Disease Study Group
    • Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. N Engl J Med. 1994;331:836-841.
    • (1994) N Engl J Med , vol.331 , pp. 836-841
    • Greenberg, G.R.1    Feagan, B.G.2    Martin, F.3
  • 5
    • 0036311105 scopus 로고    scopus 로고
    • Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: A randomized placebo-controlled study in the United States
    • DOI 10.1016/S0002-9270(02)04191-6
    • Tremaine WJ, Hanauer SB, Katz S, et al. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States. Am J Gastroenterol. 2002;97:1748-1754. (Pubitemid 34761401)
    • (2002) American Journal of Gastroenterology , vol.97 , Issue.7 , pp. 1748-1754
    • Tremaine, W.J.1    Hanauer, S.B.2    Katz, S.3    Winston, B.D.4    Levine, J.G.5    Persson, T.6    Persson, A.7
  • 7
    • 79251534064 scopus 로고    scopus 로고
    • Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease
    • quiz e413-424
    • Tromm A, Bunganic I, Tomsova E, et al. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology. 2011;140:425-434 e421; quiz e413-424.
    • (2011) Gastroenterology , vol.140
    • Tromm, A.1    Bunganic, I.2    Tomsova, E.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.